CAMILO SERRANO: Open Payments
NPI 1780744250 · CARNEYS POINT, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,674 in 118 payments from 15 companies in 2025. Trend: 2023 $1,394 · 2024 $1,556 · 2025 $1,674
Food & beverage: $1,674
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $304 |
| ABBVIE INC. | 27 | $247 |
| Teva Pharmaceuticals USA, Inc. | 16 | $197 |
| Otsuka America Pharmaceutical, Inc. | 12 | $195 |
| E.R. Squibb & Sons, L.L.C. | 11 | $160 |
| Janssen Pharmaceuticals, Inc | 5 | $120 |
| Axsome Therapeutics, Inc. | 6 | $103 |
| Alkermes, Inc. | 5 | $91 |
| Vanda Pharmaceuticals Inc. | 4 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $73 |
Products named: INGREZZA, VRAYLAR, REXULTI, COBENFY, UZEDY, Auvelity, ARISTADA, AUSTEDO XR.
Industry payments across NJ — which companies pay providers there.
